Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Br J Clin Pharmacol. 2022 Jan 26;88(3):883–893. doi: 10.1111/bcp.15177

Figure 1. Percentage change in weight from baseline to week 48 among participants in the efavirenz arm (n=154) and in the dolutegravir arm (n=231).

Figure 1